0.70
+0.0328(+4.91%)
Currency In USD
| Previous Close | 0.67 |
| Open | 0.67 |
| Day High | 0.71 |
| Day Low | 0.66 |
| 52-Week High | 3.09 |
| 52-Week Low | 0.66 |
| Volume | 163,324 |
| Average Volume | 305,738 |
| Market Cap | 88.54M |
| PE | -1.35 |
| EPS | -0.52 |
| Moving Average 50 Days | 0.74 |
| Moving Average 200 Days | 1.26 |
| Change | 0.03 |
If you invested $1000 in Nautilus Biotechnology, Inc. (NAUT) since IPO date, it would be worth $67.15 as of August 24, 2025 at a share price of $0.701. Whereas If you bought $1000 worth of Nautilus Biotechnology, Inc. (NAUT) shares 3 years ago, it would be worth $300.86 as of August 24, 2025 at a share price of $0.701.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
GlobeNewswire Inc.
Jul 30, 2025 12:00 PM GMT
• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease • Agreement links the organizations’ next-generation proteomics technology and neuroscie
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
GlobeNewswire Inc.
Jul 15, 2025 12:00 PM GMT
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results f
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating i